Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
- PMID: 27673306
- DOI: 10.1001/jama.2016.13985
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Abstract
Importance: The comparative clinical benefit of nonstatin therapies that reduce low-density lipoprotein cholesterol (LDL-C) remains uncertain.
Objective: To evaluate the association between lowering LDL-C and relative cardiovascular risk reduction across different statin and nonstatin therapies.
Data sources and study selection: The MEDLINE and EMBASE databases were searched (1966-July 2016). The key inclusion criteria were that the study was a randomized clinical trial and the reported clinical outcomes included myocardial infarction (MI). Studies were excluded if the duration was less than 6 months or had fewer than 50 clinical events. Studies of 9 different types of LDL-C reduction approaches were included.
Data extraction and synthesis: Two authors independently extracted and entered data into standardized data sheets and data were analyzed using meta-regression.
Main outcomes and measures: The relative risk (RR) of major vascular events (a composite of cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, or stroke) associated with the absolute reduction in LDL-C level; 5-year rate of major coronary events (coronary death or MI) associated with achieved LDL-C level.
Results: A total of 312 175 participants (mean age, 62 years; 24% women; mean baseline LDL-C level of 3.16 mmol/L [122.3 mg/dL]) from 49 trials with 39 645 major vascular events were included. The RR for major vascular events per 1-mmol/L (38.7-mg/dL) reduction in LDL-C level was 0.77 (95% CI, 0.71-0.84; P < .001) for statins and 0.75 (95% CI, 0.66-0.86; P = .002) for established nonstatin interventions that work primarily via upregulation of LDL receptor expression (ie, diet, bile acid sequestrants, ileal bypass, and ezetimibe) (between-group difference, P = .72). For these 5 therapies combined, the RR was 0.77 (95% CI, 0.75-0.79, P < .001) for major vascular events per 1-mmol/L reduction in LDL-C level. For other interventions, the observed RRs vs the expected RRs based on the degree of LDL-C reduction in the trials were 0.94 (95% CI, 0.89-0.99) vs 0.91 (95% CI, 0.90-0.92) for niacin (P = .24); 0.88 (95% CI, 0.83-0.92) vs 0.94 (95% CI, 0.93-0.94) for fibrates (P = .02), which was lower than expected (ie, greater risk reduction); 1.01 (95% CI, 0.94-1.09) vs 0.90 (95% CI, 0.89-0.91) for cholesteryl ester transfer protein inhibitors (P = .002), which was higher than expected (ie, less risk reduction); and 0.49 (95% CI, 0.34-0.71) vs 0.61 (95% CI, 0.58-0.65) for proprotein convertase subtilisin/kexin type 9 inhibitors (P = .25). The achieved absolute LDL-C level was significantly associated with the absolute rate of major coronary events (11 301 events, including coronary death or MI) for primary prevention trials (1.5% lower event rate [95% CI, 0.5%-2.6%] per each 1-mmol/L lower LDL-C level; P = .008) and secondary prevention trials (4.6% lower event rate [95% CI, 2.9%-6.4%] per each 1-mmol/L lower LDL-C level; P < .001).
Conclusions and relevance: In this meta-regression analysis, the use of statin and nonstatin therapies that act via upregulation of LDL receptor expression to reduce LDL-C were associated with similar RRs of major vascular events per change in LDL-C. Lower achieved LDL-C levels were associated with lower rates of major coronary events.
Comment in
-
Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.JAMA. 2017 Jan 24;317(4):439. doi: 10.1001/jama.2016.19058. JAMA. 2017. PMID: 28118443 No abstract available.
-
Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.JAMA. 2017 Jan 24;317(4):439-440. doi: 10.1001/jama.2016.19061. JAMA. 2017. PMID: 28118444 No abstract available.
-
What Is the Best Disease-Guided Approach to Statin?J Am Coll Cardiol. 2017 Feb 7;69(5):600. doi: 10.1016/j.jacc.2016.11.035. J Am Coll Cardiol. 2017. PMID: 28153119 No abstract available.
Similar articles
-
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.JAMA Cardiol. 2018 Sep 1;3(9):823-828. doi: 10.1001/jamacardio.2018.2258. JAMA Cardiol. 2018. PMID: 30073316 Free PMC article.
-
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.Circulation. 2019 Oct 15;140(16):1308-1317. doi: 10.1161/CIRCULATIONAHA.119.041998. Epub 2019 Sep 18. Circulation. 2019. PMID: 31530008 Free PMC article.
-
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.JAMA. 2018 Apr 17;319(15):1566-1579. doi: 10.1001/jama.2018.2525. JAMA. 2018. PMID: 29677301 Free PMC article. Review.
-
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.Eur Heart J. 2018 Apr 7;39(14):1172-1180. doi: 10.1093/eurheartj/ehx566. Eur Heart J. 2018. PMID: 29069377
-
Nonstatin therapies for management of dyslipidemia: a review.Clin Ther. 2015 Oct 1;37(10):2153-79. doi: 10.1016/j.clinthera.2015.09.001. Epub 2015 Sep 26. Clin Ther. 2015. PMID: 26412799 Review.
Cited by
-
Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.Lipids Health Dis. 2024 Jun 3;23(1):163. doi: 10.1186/s12944-024-02133-w. Lipids Health Dis. 2024. PMID: 38831433 Free PMC article.
-
Dyslipidemia Treatment and Cerebrovascular Disease: Evidence Regarding the Mechanism of Stroke.J Lipid Atheroscler. 2024 May;13(2):139-154. doi: 10.12997/jla.2024.13.2.139. Epub 2024 Feb 23. J Lipid Atheroscler. 2024. PMID: 38826180 Free PMC article. Review.
-
The Health Benefits of Probiotic Lactiplantibacillus plantarum: A Systematic Review and Meta-Analysis.Probiotics Antimicrob Proteins. 2024 May 31. doi: 10.1007/s12602-024-10287-3. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 38816672
-
First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults.J Res Med Sci. 2024 Mar 29;29:18. doi: 10.4103/jrms.jrms_318_23. eCollection 2024. J Res Med Sci. 2024. PMID: 38808220 Free PMC article.
-
Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach.Int J Mol Sci. 2024 May 10;25(10):5212. doi: 10.3390/ijms25105212. Int J Mol Sci. 2024. PMID: 38791250 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical